Project Grant HT94252311017
Award Date
9/15/23
Completion Date
9/14/26
Dollars Obligated
$519K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23284, USA
Similar Awards
This federal Project Grant award in the amount of $582,189.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Virginia Commonwealth University (VCU) to investigate the role of histone H2A ubiquitination and the RSF1 gene in breast cancer. The 3-year award, starting on March 1, 2024, will fund personnel, facilities, and equipment to conduct basic, translational, and clinical research aimed at advancing...
The Defense Health Agency awarded a $631,546 Project Grant to Stanford University to track sarcoma response and resistance to radiation therapy from April 15, 2022 to April 14, 2025. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative solutions for battlefield medicine. Specifically, Stanford University will use the funding to...
The Department of Defense's Defense Health Agency awarded Virginia Commonwealth University (VCU) a $568,461 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "READING HISTONE H2A UBIQUITINATION IN THE FUNCTION OF RSF1 IN BREAST CANCERS WITH RSF1 GENE AMPLIFICATION." The grant, effective from March 1, 2024 through February 28, 2027, will fund VCU's research to advance the scientific understanding of breast cancer and develop...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $712,001 Project Grant under the Military Medical Research and Development program to conduct research on understanding the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis through integrative computational biology. The three-year award runs from September 1, 2023 through August 31, 2026. Through this funding, Dana-Farber will utilize computational methods to analyze Ewing sarcoma tumor samples and related...
This federal Project Grant award, valued at $1,552,466.00, was made by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at Virginia Commonwealth University (VCU) focused on developing unique oncolytic adenoviruses to target ovarian cancer cells. The award, effective May 1, 2025 through April 30, 2029, will enable VCU researchers to pursue innovative therapeutic approaches to tackle this...
This federal Project Grant award of $523,614.37, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research into the genetic mechanisms underlying schwannomatosis and other rare conditions. The University of Manchester, a prominent research institution in the United Kingdom, will conduct this 3-year research initiative, focusing on elucidating the disease-specific genetic factors that distinguish...
The Defense Health Agency has awarded a $178,000 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "DISSECTING THE DIFFERENCE IN THE PATHOGENESIS AND IMMUNE MICROENVIRONMENT OF PEDIATRIC AND ADULT OSTEOSARCOMA". This research project falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. DFCI, a non-profit hospital and cancer...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research....
The Department of the Army Medical Command awarded a $544,250 Project Grant to the University of Washington under the Military Medical Research and Development program (CFDA 12.420) to identify epigenetic-based targets against cancer stem cells in rhabdomyosarcoma. The three-year award beginning August 1, 2022 will support research to investigate medical solutions for battlefield injuries by exploring innovative biomedical research approaches. Specifically, the University of Washington will...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...